MSN Put On Hold As DC Appeals Court Freezes Generic Entresto Approval
Novartis Has Met ‘Stringent Requirements’ For Stay Of ANDA Approval Pending Appeal
MSN Laboratories will be unable to move forward – for now – with any potential ‘at-risk’ launch for its generic version of Novartis’ Entresto blockbuster in the US after the originator won a stay on the firm’s ANDA pending appeal from the US Court of Appeals for the District of Columbia Circuit.
